🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Amazing CV Research Day celebration @VUMC_heart with Alan Daugherty giving keynote address. Congrats AzuahTheShort 🦋 @azuahtheshort.bsky.social in Amanda Doran for best student abstract. Record turnout to promote cardiovascular science @VUMCResearch.

Thanks @nanostringtech for selecting me for the grant, can’t wait to use the CVD pathophysiology panels to advance my research!

The median time of onset of ICI-myocarditis is ~30-60 days In our patient, it occurred at 987 days We report a case of fulminant late onset ICI-myocarditis. Hoping to raise awareness for late onset irAEs Han Zhu Sean M Wu, MD PhD Ronald Witteles JACC Journals jacc.org/doi/10.1016/j.…

#OriginalResearch: In a meta-analysis of 8 studies, 6,000 to 9,000 steps/day was associated with 40% to 50% lower risk of CVD among older adults #AHAJournals ahajrnls.org/3WgtECd

1/ We are delighted to see our study on the effect of sucralose on T-cells was published today in nature! Time for a tweetorial 🧐 (with GIFs 🤠)

Excited to share a portion of my thesis work soon! For those who can’t attend in person, please reach out and I will share a zoom link!

Hypertension is the leading modifiable risk factor for worldwide morbidity & mortality. This study describes the role of T cells in hypertension & hypertensive end-organ damage & outlines potential therapeutic targets bit.ly/KID090 Daniel Fehrenbach Matt Alexander Meena Madhur

Excited to see this officially out!

Join us in one week as Thao Le, MD, PhD (she/her), graduate student in the lab of Julio Ayala (Julio Ayala), defends her thesis titled "Identification of Intracellular and Physiological Targets Transducing the Weight-Lowering Actions of Glucagon-Like Peptide 1 Receptor Agonists!" Vanderbilt MSTP

Clinical benefits of #SGLT2is in #HF do not appear to be mediated by changes in myocardial #energetics based on this small mechanistic RCT conducted in patients with #HFrEF & #HFpEF #EMPAVISION ahajournals.org/doi/10.1161/CI…

Many thanks to all my coauthors who made this possible! Excited to share this story in its final form

First oral semaglutide made a strong impression in OASIS-1 #obesity with 15% #weightloss now orforglipron leads the impressive pack of new small molecule oral GLP-1RA with robust #Weightloss and good tolerability ADA2023

Celebrating our transitions and next steps #Madhur Lab #Alexander Lab #WillMissThisGang!! ⁦Daniel Fehrenbach⁩ ⁦Duncan Smart PhD⁩ ⁦Jean Wassenaar⁩ ⁦Matt Alexander⁩ ⁦Vanderbilt PSTP/Harrison Society⁩ ⁦@VUMC_Medicine⁩ ⁦@VUMCClinPharm⁩ #GreenHillsGrille

Cardiometabolic Effects of DOCA-salt in Mice Depend on Ambient Temperature @JLGrobe Eva Fekete Pablo Nakagawa Curt D. Sigmund, PhD ahajrnls.org/45tWDH0

Woah. CCR2+ myeloid cell imaging in the human heart. Can’t wait to see this applied more broadly in CV diseases. Amazing work from Lavine at al. Great example of translating mechanistic preclinical findings to humans

When Einthoven introduced the ECG to the world, he uniquely labeled its parts PQRST, inspired by mathematicians who used Ps & Qs in coordinates. Yet, he believed there was more to find, so he started in the alphabet's middle, leaving room for new discoveries on both sides. 1/n

Thank you CVR Tomasz Guzik and European Society of Cardiology Journals for highlighting our recent publication with this invited editorial! academic.oup.com/cardiovascres/… Duncan Smart PhD Daniel Fehrenbach Amanda Doran Jean Wassenaar #HeartFailure #Trem2 #cardioimmunology

Excited to join the #JACCBTS social media team—it has quickly become a journal in which to find and publish high-quality cardiovascular research. Follow the entire team for more great work published in #JACCBTS! Jeff Hsu, MD, PhD Matt Alexander Jean Wassenaar JACC Journals

Looking forward to working with Michael Raddatz Jeff Hsu, MD, PhD and @VasRes to learn about all the exciting translational work coming out of #JACCBTS!

Single subcutaneous doses of zilebesiran significantly lower blood pressure for up to 6 months, suggesting potential for use as an effective antihypertensive with quarterly or biannual dosing. Read the KARDIA-1 RCT: ja.ma/48jbBAy